|
STRN expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.80399999569903E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.97639999997146E-07 |
| Normal-vs-Stage2 |
2.27500000005154E-06 |
| Normal-vs-Stage3 |
2.24120000003047E-06 |
| Normal-vs-Stage4 |
1.777580E-04 |
| Stage1-vs-Stage2 |
3.241600E-01 |
| Stage1-vs-Stage3 |
6.825000E-01 |
| Stage1-vs-Stage4 |
9.232400E-01 |
| Stage2-vs-Stage3 |
5.254600E-01 |
| Stage2-vs-Stage4 |
4.698200E-01 |
| Stage3-vs-Stage4 |
8.475200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.08740000004381E-06 |
| Normal-vs-AfricanAmerican |
1.652240E-02 |
| Normal-vs-Asian |
4.45739999999084E-06 |
| Caucasian-vs-AfricanAmerican |
5.050600E-01 |
| Caucasian-vs-Asian |
3.859200E-01 |
| AfricanAmerican-vs-Asian |
2.304200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.68130020595481E-10 |
| Normal-vs-Female |
2.46010000004571E-06 |
| Male-vs-Female |
1.732410E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.28819999999308E-05 |
| Normal-vs-Age(41-60Yrs) |
1.41510000384315E-08 |
| Normal-vs-Age(61-80Yrs) |
2.16880000003528E-06 |
| Normal-vs-Age(81-100Yrs) |
6.324600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.142570E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.105400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.219800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.836800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.091800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.609400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.465600E-01 |
| Classical-VS-Follicular |
5.609400E-04 |
| Classical-VS-Other |
6.228100E-02 |
| Classical-VS-Normal |
3.77940000000354E-05 |
| Tall-VS-Follicular |
8.492400E-02 |
| Tall-VS-Other |
1.103180E-01 |
| Tall-VS-Normal |
1.504480E-03 |
| Follicular-VS-Other |
4.051000E-01 |
| Follicular-VS-Normal |
4.74440042808055E-10 |
| Other-VS-Normal |
5.627900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.66040003968249E-09 |
| Normal-vs-N1 |
1.581020E-04 |
| N0-vs-N1 |
4.520800E-01 |
|
|
